ArticleMultiple sclerosis journal - experimental, translational and clinical
Epidemiology of neuromyelitis optica spectrum disease in Central-West Brazil: Prevalence and associated clinical and demographic features.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuromyelitis optica spectrum diseases (NMOSD) are rare autoimmune diseases of the central nervous system. Although Brazil reports one of the highest global prevalences of NMOSD, regional data, particularly from the Central-West, remain limited. Objectives: To characterize the epidemiological, laboratory, and therapeutic profiles of NMOSD patients residing in Brazil's Federal District, based on 2015 international diagnostic criteria. Methods: This prospective observational study analyzed data from 55 consecutive NMOSD patients entered as new records in the Brazilian Registry of Neurological Diseases (REDONE.br) between July 2023 and July 2025. Statistical analyses included descriptive methods, between-group comparisons, and multivariable logistic-regression. Results: The cohort comprised 45 women (81.8%), with a mean age of onset of 36.85 ± 14.89 years. Myelitis was the most frequent initial presentation (76.4%), followed by unilateral optic neuritis (45.5%). The socioeconomic profile revealed marked vulnerability: 65.5% reported family income ≤2 minimum wages, and 45.5% were unemployed. Rituximab was the most frequently used disease-modifying therapy. The estimated NMOSD prevalence was 1.84 cases per 100,000 inhabitants (95% CI: 1.38-2.39), and the prevalence of antiAQP4 + was 1.64 cases per 100,000 (95% CI: 1.21-2.16). Conclusions: This study provides a comprehensive characterization of NMOSD in Brazil's Central-West region and highlights that the disease disproportionately affects individuals living in conditions of social vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.